Ocumetics Technology Corp
Ocumetics Technology Corp. engages in research, development, production, and sale of vision enhancement products in Canada. The company develops expandable intraocular lenses to eliminate the need for corrective lenses primarily for people over 45 years of age. The company was formerly known as Quantum Blockchain Technologies Ltd. and changed changed its name to Ocumetics Technology Corp. in Augu… Read more
Ocumetics Technology Corp (OTCFF) - Net Assets
Latest net assets as of September 2025: $-3.88 Million USD
Based on the latest financial reports, Ocumetics Technology Corp (OTCFF) has net assets worth $-3.88 Million USD as of September 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($1.63 Million) and total liabilities ($5.52 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $-3.88 Million |
| % of Total Assets | -237.88% |
| Annual Growth Rate | N/A |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | 1068.09 |
Ocumetics Technology Corp - Net Assets Trend (2021–2024)
This chart illustrates how Ocumetics Technology Corp's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Ocumetics Technology Corp (2021–2024)
The table below shows the annual net assets of Ocumetics Technology Corp from 2021 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | $-1.94 Million | -2225.30% |
| 2023-12-31 | $91.10K | -89.12% |
| 2022-12-31 | $837.40K | +409.58% |
| 2021-12-31 | $-270.50K | -- |
Equity Component Analysis
This analysis shows how different components contribute to Ocumetics Technology Corp's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 1037267400.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Other Components | $10.26 Million | % |
| Total Equity | $-1.94 Million | 100.00% |
Ocumetics Technology Corp Competitors by Market Cap
The table below lists competitors of Ocumetics Technology Corp ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
KEBNI AB SER.B
F:KEN
|
$18.47 Million |
|
Ekiz Kimya Sanayi ve Ticaret AS
IS:EKIZ
|
$18.48 Million |
|
Elektroimportoren As
OL:ELIMP
|
$18.48 Million |
|
Baydoner Restoranlari A.S.
IS:BYDNR
|
$18.48 Million |
|
SOL-GEL TECHN. IS-10
F:4SG
|
$18.46 Million |
|
NatureWise Biotech & Medicals Corporation
TWO:4732
|
$18.46 Million |
|
PANTECH GLOBAL BERHAD
KLSE:5331
|
$18.46 Million |
|
Diatreme Resources Ltd
AU:DRX
|
$18.45 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Ocumetics Technology Corp's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 91,104 to -1,936,231, a change of -2,027,335 (-2225.3%).
- Net loss of 3,022,158 reduced equity.
- New share issuances of 256,600 increased equity.
- Other factors increased equity by 738,223.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-3.02 Million | -156.08% |
| Share Issuances | $256.60K | +13.25% |
| Other Changes | $738.22K | +38.13% |
| Total Change | $- | -2225.30% |
Book Value vs Market Value Analysis
This analysis compares Ocumetics Technology Corp's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2021-12-31 | $0.00 | $0.25 | x |
| 2022-12-31 | $0.01 | $0.25 | x |
| 2023-12-31 | $0.00 | $0.25 | x |
| 2024-12-31 | $-0.02 | $0.25 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Ocumetics Technology Corp utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 0.00%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 0.00%
- • Asset Turnover: 0.00x
- • Equity Multiplier: 0.00x
- Recent ROE (0.00%) is above the historical average (-1066.13%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2021 | 0.00% | 0.00% | 0.00x | 0.00x | $-571.14K |
| 2022 | -265.10% | 0.00% | 0.00x | 1.64x | $-2.30 Million |
| 2023 | -3999.43% | 0.00% | 0.00x | 11.38x | $-3.65 Million |
| 2024 | 0.00% | 0.00% | 0.00x | 0.00x | $-2.83 Million |
Industry Comparison
This section compares Ocumetics Technology Corp's net assets metrics with peer companies in the Medical Instruments & Supplies industry.
Industry Context
- Industry: Medical Instruments & Supplies
- Average net assets among peers: $771,083,081
- Average return on equity (ROE) among peers: -146.50%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Ocumetics Technology Corp (OTCFF) | $-3.88 Million | 0.00% | N/A | $18.47 Million |
| ANGELALIGN TECHNOLOGY INC (AGLFF) | $520.03 Million | 8.62% | 0.25x | $405.57 Million |
| Akoya Biosciences Inc (AKYA) | $-30.16 Million | 0.00% | 0.00x | $16.24 Million |
| Alcon AG (ALC) | $2.56 Billion | 36.42% | 1.05x | $36.83 Billion |
| Align Technology Inc (ALGN) | $161.15 Million | 22.17% | 0.38x | $11.50 Billion |
| AngioDynamics Inc (ANGO) | $372.19 Million | 2.67% | 0.10x | $344.14 Million |
| Ansell Limited (ANSLF) | $1.56 Billion | 10.20% | 0.61x | $2.58 Billion |
| AptarGroup Inc (ATR) | $2.07 Billion | 11.57% | 1.03x | $7.93 Billion |
| AtriCure Inc (ATRC) | $483.76 Million | 10.38% | 0.27x | $1.38 Billion |
| Avinger Inc (AVGR) | $4.24 Million | -1323.46% | 11.63x | $1.26 Million |
| Anteris Technologies Global Corp. Common Stock (AVR) | $18.90 Million | -243.53% | 0.62x | $156.14 Million |